1. Home
  2. AMRX vs GRFS Comparison

AMRX vs GRFS Comparison

Compare AMRX & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amneal Pharmaceuticals Inc.

AMRX

Amneal Pharmaceuticals Inc.

HOLD

Current Price

$21.24

Market Cap

6.4B

Sector

Health Care

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$7.93

Market Cap

5.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMRX
GRFS
Founded
2002
1940
Country
United States
Spain
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4B
5.2B
IPO Year
2018
2008

Fundamental Metrics

Financial Performance
Metric
AMRX
GRFS
Price
$21.24
$7.93
Analyst Decision
Strong Buy
Buy
Analyst Count
7
2
Target Price
★ $23.00
$10.37
AVG Volume (30 Days)
★ 2.8M
493.6K
Earning Date
11-03-2026
07-28-2022
Dividend Yield
N/A
★ 1.34%
EPS Growth
★ 157.89
N/A
EPS
★ 0.37
N/A
Revenue
N/A
N/A
Revenue This Year
$4.56
$1.93
Revenue Next Year
$9.33
$6.23
P/E Ratio
$56.70
★ $18.67
Revenue Growth
N/A
N/A
52 Week Low
$9.99
$6.96
52 Week High
$21.18
$9.90

Technical Indicators

Market Signals
Indicator
AMRX
GRFS
Relative Strength Index (RSI) 66.74 64.14
Support Level $16.59 $7.87
Resistance Level N/A $7.99
Average True Range (ATR) 0.64 0.16
MACD 0.06 0.05
Stochastic Oscillator 93.21 79.17

Price Performance

Historical Comparison
AMRX
GRFS

About AMRX Amneal Pharmaceuticals Inc.

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

About GRFS Grifols S.A.

Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.

Share on Social Networks: